Investigate / DHR
Understand DANAHER CORP /DE/
Can acquisitions and the Danaher Business System continue to improve its portfolio, or do economic, competitive and customer-demand pressures outweigh them?
Snapshot reviewed 2026-10-02. Source published 2026-07-21. No account needed.
AI-assisted synthesis of selected public filings, checked against the cited excerpts. Not a complete analysis.
This is a research starting point, not a buy/sell recommendation or a current valuation. New developments after these sources are not incorporated automatically.
Your research workspace / DHR
Ask better questions. Keep the evidence.
Explore the available sources for DANAHER CORP /DE/, then keep what deserves another look.
01 Investor activity
Who reports owning DHR?
13 tracked reported owners. Disclosures are delayed and may describe different quarters—not live holdings or stated motives.
02 Business evidence
Reported evidence
What does the company do?
Danaher operates science and technology businesses in Biotechnology, Life Sciences and Diagnostics, with many products and services typically sold on a recurring basis.
Latticework interpretation
What could support the case?
If management can identify, complete and effectively integrate suitable acquisitions, those deals could support overall growth and operating results, since the filing says this ability affects both.
Latticework interpretation
What could break the case?
If growth slows or markets deteriorate for a significant period, or economic improvements do not reach Danaher's served markets, its business and financial statements could be adversely affected.
03 Questions to investigate
Open saved takeaways →Read the full company brief
1. Understand the business
Danaher operates science and technology businesses in Biotechnology, Life Sciences and Diagnostics, with many products and services typically sold on a recurring basis.
Source: Annual filing · business description ↗2. What the reported results show
Latest source: 10-Q, reporting period ended 2026-06-26. Selected reported US-GAAP/USD comparisons. The period and basis of each measure are shown separately; year-to-date cash flow is not a quarterly figure. Missing comparisons are collection gaps, not evidence that a company has no revenue or earnings.
| Measure | Current | Prior year |
|---|---|---|
| Revenue from customer contracts ↗Quarter: 2026-03-28–2026-06-26; prior 2025-03-29–2025-06-27Both values reported in the current filing. Excludes assessed tax; this concept may exclude other company revenue. | $6,265m | $5,936m |
| Operating income ↗Quarter: 2026-03-28–2026-06-26; prior 2025-03-29–2025-06-27Both values reported in the current filing. | $1,127m | $760m |
| Net income ↗Quarter: 2026-03-28–2026-06-26; prior 2025-03-29–2025-06-27Both values reported in the current filing. | $870m | $555m |
| Operating cash flow ↗Six months (year to date): 2026-01-01–2026-06-26; prior 2025-01-01–2025-06-27Both values reported in the current filing. Operating cash flow is not free cash flow or a standalone solvency assessment; inspect the full statement. | $2,856m | $2,637m |
Comparison caveat: The prior profit period included a genomics trade-name impairment. The absence of that charge affects the comparison; the profit increase is not purely underlying demand growth.
10-Q · latest checked financial statements and discussion ↗3. The investment debate
Latticework interpretation of the reported results—not the stated motives of any investor.
What could support the case
If management can identify, complete and effectively integrate suitable acquisitions, those deals could support overall growth and operating results, since the filing says this ability affects both.
Supporting filing ↗The strongest caution
If growth slows or markets deteriorate for a significant period, or economic improvements do not reach Danaher's served markets, its business and financial statements could be adversely affected.
Caution evidence ↗An interesting business is not necessarily an attractive investment at today's price. Price, dilution, financing terms and a valuation range still need investigation.
Inspect the evidence behind both sides ↗4. Three questions worth investigating
Use these to guide your research, not as conclusions that have already been proved.
Does recurring-type revenue hold up when demand weakens?
Starting evidence: Danaher describes many products and services as typically sold on a recurring basis, primarily through direct sales to a geographically diverse customer base.
Investigate next: Compare the recurring versus nonrecurring revenue split by segment across multiple filings, and read management commentary on order cancellations and sales cycles.
Read the supporting filing ↗How exposed is it to competitive price pressure?
Starting evidence: Danaher operates in intensely competitive, consolidating industries and may need to lower prices even if it competes effectively.
Investigate next: Review segment-level margin discussion and any commentary on pricing and market share against named competitors in the full annual report.
Read the supporting filing ↗Will new products be accepted by customers?
Starting evidence: Growth is described as depending on timely development, commercialization and customer acceptance of new and enhanced technology-based products and services.
Investigate next: Look at research and development disclosures, new product commentary and segment growth explanations in the latest 10-Q and 10-K.
Read the supporting filing ↗5. Decide what to do next
Worth another look? Save this company and return to the evidence. Writing a private view is optional. You do not need to decide whether to invest today.
Save is on this device. Recording a private view requires sign-in and an explicit save. Neither action subscribes you to email or automatically evaluates your thesis.